Vizient Surveys Impact of AI in Healthcare, Advancements in Pediatric Gene Therapy

Donna Ledbetter
(972) 830-6321
donna.ledbetter@vizientinc.com

In its latest Pediatric Tech Watch, Vizient, Inc. surveys the impact of artificial intelligence (AI) in healthcare, advancements in pediatric gene therapy and rounds up the latest updates for pediatric immunizations. Read Pediatric Tech Watch.

“The unique needs of the pediatric population require specialized solutions,” said Sarah Herrmann, Vizient director of program services. “From efficient space planning and supply continuity to exploring new cell and gene therapies, providers must address these challenges and stay informed about new advancements to meet the needs of young patients, guarantee access to essential pediatric medical supplies and deliver quality care.”

Featured articles in this edition of Pediatric Tech Watch include:

The impact of AI in pediatric healthcare — Hospitals across the United States are experimenting with AI to improve efficiency and patient outcomes. Driving the rise of AI adoption are consumers’ digital familiarity, growing data volume and rapid software sophistication. This article surveys how hospitals are leveraging the new technology and the return on investment they’re finding. Benefits range from improved coding to enhanced patient access and more.

Advancements in pediatric gene therapy: A new hope for treating genetic disorders — Groundbreaking gene and cell therapies offer new hope for children suffering from severe genetic disorders, such as Duchenne muscular dystrophy and spinal muscular atrophy. With these advancements, many institutions are having to address how to identify eligible patients, the necessary bed space or equipment, post-treatment follow-up protocols and the overall financial impact to the healthcare system to offer these complex and expensive treatments.

Pediatric immunization update — This article rounds up the latest vaccine news for influenza, DTaP-IPV-Hib-HepB, respiratory syncytial virus and COVID. Data continues to show the importance of COVID-19 vaccination to protect children against hospitalization and death due to infection. The Centers for Disease Control and Prevention and Advisory Committee on Immunization Practices recommends everyone 6 months of age and older receive an updated influenza vaccine for the 2024-25 season. Of note, this season’s influenza vaccine will shift from a quadrivalent to a trivalent vaccine.

Read more about Pediatric Tech Watch.

About Vizient, Inc.

Vizient, Inc., the nation's largest provider-driven healthcare performance improvement company, serves more than 65% of the nation's acute care providers, including 97% of the nation's academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241024514581/en/

The unique needs of the pediatric population require specialized solutions.